Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The BPDCN Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning
Latest videos The BPDCN Sessions Conferences Topics Podcasts Expert Editorial Board

Welcome to The BPDCN Channel

Reporting from key international congresses and speaking with world-leading experts, VJHemOnc brings you the latest advances in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematological malignancy. The BPDCN Channel delivers regular video interviews, roundtable discussions, and podcasts, so that you can keep up-to-date with all the practice-changing developments in BPDCN.

Explore The BPDCN Channel to learn about the latest clinical trial updates and novel agents being investigated.

Conferences

EHA 2025
ASCO 2025
ASH 2024
MPN Workshop of the Carolinas 2024
EHA 2024
EBMT 2024
1:11
Improving outcomes for patients with BPDCN: alloSCT and maintenance therapy
Eric Deconinck • 13 Jun 2025
1:23
First-line treatment selection for patients with blastic plasmacytoid dendritic cell neoplasm
Eric Deconinck • 13 Jun 2025
1:23
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
Eric Deconinck • 13 Jun 2025
1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025
View All Videos
1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
2:00
Efficacy and safety of pivekimab sunirine in patients with BPDCN: CADENZA study update
Naveen Pemmaraju • 1 Jun 2025
1:48
Long-term safety and efficacy of tagraxofusp in BPDCN: results from a subgroup analysis
Naveen Pemmaraju • 1 Jun 2025
View All Videos
2:11
Treatment results of the tagraxofusp cohort of the BPDCN international registry
Astghik Voskanyan • 9 Dec 2024
1:15
Tagraxofusp demonstrates anti-tumor activity without myelosuppression in patients with BPDCN
Marina Konopleva • 8 Dec 2024
2:28
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
Shai Shimony • 8 Dec 2024
View All Videos
2:09
Five-year post-approval updates: tagraxofusp in the treatment of BPDCN
Naveen Pemmaraju • 23 Aug 2024
2:13
Major breakthroughs in the field of BPDCN: combination therapies, managing CNS involvement & more
Naveen Pemmaraju • 23 Aug 2024
2:20
Best practices when using tagraxofusp for the treatment of BPDCN
Naveen Pemmaraju • 23 Aug 2024
View All Videos
2:57
Novel targeted therapies for the treatment of BPDCN
Muzaffar Qazilbash • 30 Jul 2024
3:36
The long-term outcomes of consolidative alloSCT for BPDCN
Muzaffar Qazilbash • 30 Jul 2024
2:32
Tools and biomarkers being used for the diagnosis of BPDCN
Muzaffar Qazilbash • 30 Jul 2024
1:12
Clinical implications of extramedullary manifestations in CMML
Guillermo Montalban-Bravo • 15 Jun 2024
View All Videos
1:51
Common clinical manifestations of BPDCN and the major challenges in its diagnosis
Cristina Papayannidis • 22 Apr 2024
2:03
Current SoC for BPDCN and other emerging treatment options
Cristina Papayannidis • 22 Apr 2024
1:27
First-line tagraxofusp followed by alloSCT in BPDCN: a case study
Cristina Papayannidis • 22 Apr 2024
1:07
Key advancements in the treatment of BPDCN from EBMT 2024
Cristina Papayannidis • 22 Apr 2024
View All Videos

Topics

Treatment
Immuno-Oncology
Diagnosis
Trial updates
1:11
Improving outcomes for patients with BPDCN: alloSCT and maintenance therapy
Eric Deconinck • 13 Jun 2025
1:23
First-line treatment selection for patients with blastic plasmacytoid dendritic cell neoplasm
Eric Deconinck • 13 Jun 2025
1:23
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
Eric Deconinck • 13 Jun 2025
1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025
View All Videos
2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
1:55
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Naveen Pemmaraju • 31 May 2025
2:00
Efficacy and safety of pivekimab sunirine in patients with BPDCN: CADENZA study update
Naveen Pemmaraju • 1 Jun 2025
1:48
Long-term safety and efficacy of tagraxofusp in BPDCN: results from a subgroup analysis
Naveen Pemmaraju • 1 Jun 2025
View All Videos
1:56
Ongoing research and unmet needs in BPDCN
Cristina Papayannidis • 17 Mar 2025
2:28
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
Shai Shimony • 8 Dec 2024
2:32
Tools and biomarkers being used for the diagnosis of BPDCN
Muzaffar Qazilbash • 30 Jul 2024
Aiming to advance the diagnosis and treatment of CMML and BPDCN
Daniel Wisemanet al. • 18 Jul 2024
View All Videos
2:06
An update on the CADENZA study: investigating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 15 Jun 2025
2:00
Efficacy and safety of pivekimab sunirine in patients with BPDCN: CADENZA study update
Naveen Pemmaraju • 1 Jun 2025
1:46
Tagraxofusp combined with azacitidine and venetoclax in the treatment of BPDCN and AML
Andrew Lane • 26 Feb 2024
1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
View All Videos

If you are interested in becoming a supporter of The BPDCN Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals